Therefore, the failure of rapamycin (sirolimus) and its analog CCI-779 (temsirolimus)42,43 to suppress mTORC2 signaling, as well as 4E-BP1 phosphorylation in GBM patients, may contribute to clinical resistance. This evidence concerns the gene EIF4EBP1 and glioblastoma.